

| <i>Product Licence Number</i> | <i>Company Name</i> | <i>Product Name</i> | <i>Active Ingredients</i> | <i>Indications for use (Non-prescription items only)</i> | <i>Marketing Outlet</i> | <i>Date of Issue</i> |
|-------------------------------|--------------------------------------|--|--|--|-----------------------------|--------------------------|
| PL3365/4007 | Sandoz Speciality Pest Control | Sendran Flea and Tick Collar for Dogs | Propoxur 9.40% w/w | | | |
| PL3832/4041 | SmithKline Beecham Animal Health Ltd | Combined Newcastle Disease and Infectious Bronchitis | Newcastle Disease | | | |
| PL1300/4010 | Sorex Ltd | Barricade 5% EC | Cypermethrin Technical 5.0% wv | | | |
| PL1598/4052 | Solvay Animal Health | Salfuride 14.66% | Nifursol | | | |
| PL1598/4011 | Solvay Animal Health | Salfuride 44% | Nifursol | | | |
| PL0286/4049 | Syntex Ltd | Synanthic IR | Oxfendazole | | | |
| PL0032/4090 | Upjohn Ltd | Lincocin Soluble Powder | Lincomycin 400 mg | | | |
| PL0032/4019 | Upjohn Ltd | Promone E 50 mg/ml | Meoroxyprogesterone Acetate B.Vet C 50 mg | | | |
| PL0032/4005 | Upjohn Ltd | Linco-Spectin 100 | Spectinomycin Sulphate Lincomycin Hydrochloride | | | |
| PL0100/4088 | Willows Francis Ltd | Scorprin 240 Injectable Solution | Trimethoprim Sulphadiazine | | | |
| PL1443/4000 | Wynmouth Lehar Ltd | D.O.T | Dinitolmide | | | |

DEPARTMENT OF HEALTH MEDICINES CONTROL AGENCY

Market Towers, 1 Nine Elms Lane, London SW8 5NQ. Telephone 071-273 0422 or 0425

Product Licences Granted

| <i>Product Licence Number</i> | <i>Company Name</i> | <i>Product Name</i> | <i>Active Ingredients</i> | <i>Indications</i> | <i>Date of Authorisation</i> |
|-------------------------------|---|---|--|---|----------------------------------|
| 0003/0304 | The Wellcome Foundation Limited | Zovirax Cold Sore Cream | Acylovir 5% w/w | Pharmacy Medicine Zovirax Cold Sore Cream is indicated for the treatment of herpes simplex virus infections of the lips and face. | 14th May 1993 |
| 0003/0317 | The Wellcome Foundation Limited | Sudafed Tablets | Pseudoephedrine Hydrochloride BP 60.0 mg | Pharmacy Medicine Sudafed is a decongestant of the mucous membranes of the upper respiratory tract, especially the nasal mucosa and sinuses, and is indicated for the symptomatic relief of conditions such as allergic rhinitis, vasomotor rhinitis, the common cold and influenza. | 14th May 1993 |
| 0003/0323 | The Wellcome Foundation Limited | Alkeran Injection (Freeze Dried) 50 mg | Melphalan BP 50.0 mg | Prescription Only Medicine Alkeran Injection, at conventional intravenous dosage, is indicated in the treatment of multiple myeloma and ovarian cancer. Alkeran Injection, at high intravenous dosage, is indicated with or without autologous bone marrow transplantation, for the treatment of multiple myeloma and childhood neuroblastoma. Alkeran Injection, administered by regional arterial perfusion, is indicated in the treatment of localised malignant melanoma of the extremities and localised soft tissue sarcoma of the extremities. In the above indications Alkeran may be used alone or in combination with other cytotoxic drugs. | 26th May 1993 |
| 0003/0324 | The Wellcome Foundation Limited | Solvent-Diluent (for Alkeran Injection) | None stated | Prescription Only Medicine Used to reconstitute Alkeran Injection. | 26th May 1993 |
| 0010/0171 | Bayer Plc | Glucobay 50 | Acarbose HSE 50.00 mg | Prescription Only Medicine Glucobay is recommended for the treatment of non-insulin dependent (NIDDM) diabetes mellitus in patients inadequately controlled on diet alone, or on diet and oral hypoglycaemic agents. | 28th May 1993 |
| 0010/0172 | Bayer Plc | Glucobay 100 | Acarbose HSE 100.00 mg | Prescription Only Medicine Same as in PL 0010/0171 | 28th May 1993 |
| 0011/0195 | John Wyeth and Brother Limited T/A Wyeth Laboratories | Menocal Chewable Capsules | Calcium Carbonate BP 1.268 GR | Pharmacy Medicine 1. As an adjunct to conventional therapy in the arrest or slowing down of bone demineralisation in osteoporosis. 2. In the arrest or slowing down of bone demineralisation in osteoporosis where other effective treatment is contra-indicated. | 4th May 1993 |